Ark Make investments analyst breaks down Adaptive Biotechnologies and Invitae
Chad Robins, CEO of Adaptive Biotechnologies.
Anjali Sundaram | CNBC
Ark Make investments analyst Simon Barnett on Monday defined the agency’s method to what it calls the genomic revolution, breaking down two of its favourite holdings: Adaptive Biotechnologies and Invitae.
In an interview on CNBC’s “Closing Bell,” Barnett mentioned the Cathie Wooden-led Ark Make investments sees main potential for traders within the department of molecular biology referred to as genomics, calling it “one of the crucial transformative funding alternatives of the century.”
Ark’s household of funds consists of the Genomic Revolution ETF (ARKG), which seeks to supply traders publicity to areas resembling DNA sequencing expertise and molecular diagnostics.
ARKG is down about 7% yr up to now.
Nonetheless, up to now 12 months, the ETF has risen roughly 160%. The agency’s flagship fund is the Ark Innovation ETF (ARKK), which has fallen about 1.6% to this point in 2021. ARKK is also up practically 160% up to now 12 months.
European Stocks Slide to Two-Month Low on China and Fed Concerns
(Bloomberg) — European stocks slid to the lowest level in two months as China’s real estate crackdown and worries ahead…
September is starting to stink for the stock market: Morning Brief
This article first appeared in the Morning Brief. Get the Morning Brief sent directly to your inbox every Monday to…